Argus raised the price target for the Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) stock from “a Hold” to “a Buy”. The rating was released on December 07, 2022, according to finviz. We previously noted in another research note published on November 09, 2022 by Goldman that upgraded the stock from a Neutral to a Buy with a price target of $23 for MDRX stock. The research report from Piper Sandler has resumed the stock to Overweight, with a price target set at $17. In their research brief published July 12, 2022, Goldman analysts initiated the Allscripts Healthcare Solutions Inc. stock to Neutral with a price target of $21.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) dipped -2.28% to close Tuesday’s market session at $18.03, lower as compared to yesterday’s close. The stock price fluctuated between $17.77 and $18.435 throughout the trading session with the volume trading being 1145185 shares, which represented a significant variation when compared to the three months average volume of 1.32 million shares. The firm’s stock price fluctuated -5.40% within the last five trades and -0.11% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 19.48% in the last 6 months and 26.53% was added to its value over the previous 3 months. MDRX stock is trading at a margin of -0.51%, -1.16% and 4.93% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, MDRX deals in the Healthcare domain. The stock is trading -22.45 percent below its 52-week high and 32.67 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -7.12. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Allscripts Healthcare Solutions Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 8.10 percent and the profit margin is 7.20 percent, and the company has reported a gross margin of 48.40 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $1.96 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) is 19.16. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 18.34. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 2.34 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.69, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Vakharia Tejal, the SVP General Counsel at Allscripts Healthcare Solutions Inc. (MDRX) has sold 8,642 shares of firm on Dec 12 at a price of $18.42 against the total amount of $0.16 million. In another inside trade, Stevens David B, Director of Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) sold 43,134 shares of the firm on Dec 06 for a total worth of $0.8 million at a price of $18.47. An inside trade which took place on Nov 16, CEO of Allscripts Healthcare Solutions Inc. Poulton Richard J. sold 10,000 shares of firm against total price of $0.18 million at the cost of $18.06 per share.